Friday, January 08, 2021 7:05:31 PM
I'm still concerned that CytoDyn has not filed an 8K to demonstrate payment to Samsung Biologics for the $28M payment which was scheduled for the end of last month.
In the absence of responses, I had too clarify this in my mind so that I and hopefully others can benefit....so, I did some research.
I looked closely into AB Volvo (VLVLY) to see if they made 8K filings to pay their suppliers for the radios or tires they install in/on their cars. Because Volvo contracts out for these items since they don't manufacture them in house. Couldn't find one 8K on this.
Then I again looked closely at all the 8K filings for Restaurant Brands International Inc. (RBI). You may know then by one of their subsidiaries Burger King. Again I drew a blank on finding 8K filings demonstrating they paid for supplies such as meat patties, pickles, bun, etc. Again, RBI/Burger King has to contract out these items since they don't make them in house.
Would you believe it. Not ONE 8K filing to be found for a company paying for materials that their businesses depend on for selling their product.
I'm pretty sure the 8K filings are NOT made by CYDY to inform stockholders and the public that they have paid their bills and received their supplies.
With that I hope this issue is closed as to why CytoDyn has not filed an 8K with respect to paying one of their suppliers - Samsung Biologics.
-Whataboutdat ?
In the absence of responses, I had too clarify this in my mind so that I and hopefully others can benefit....so, I did some research.
I looked closely into AB Volvo (VLVLY) to see if they made 8K filings to pay their suppliers for the radios or tires they install in/on their cars. Because Volvo contracts out for these items since they don't manufacture them in house. Couldn't find one 8K on this.
Then I again looked closely at all the 8K filings for Restaurant Brands International Inc. (RBI). You may know then by one of their subsidiaries Burger King. Again I drew a blank on finding 8K filings demonstrating they paid for supplies such as meat patties, pickles, bun, etc. Again, RBI/Burger King has to contract out these items since they don't make them in house.
Would you believe it. Not ONE 8K filing to be found for a company paying for materials that their businesses depend on for selling their product.
I'm pretty sure the 8K filings are NOT made by CYDY to inform stockholders and the public that they have paid their bills and received their supplies.
With that I hope this issue is closed as to why CytoDyn has not filed an 8K with respect to paying one of their suppliers - Samsung Biologics.
-Whataboutdat ?
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM

